If you’re a former Biogen (NASDAQ: BIIB) investor like me, you might feel compelled to warn other people away from the stock. Since the U.S. Food and Drug Administration (FDA) approved its controversial Alzheimer’s drug Aduhelm in mid-2021, very little has gone right for the pharma company. When Aduhelm was approved on June 7, Biogen’s stock shot up wildly, as the market expected that the FDA would decline to let it proceed.
Shopping Cart